ImmunityBio, Inc. IBRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$854.6M-143% | -$351.47M-0.8% | -$348.69M+5.0% | -$367.17M+10.3% | -$409.18M+1.1% | ||
| $16.08M+3.5% | $15.53M-1.7% | $15.8M-3.1% | $16.3M-3.1% | $16.83M-4.1% | ||
| $35.44M-3.7% | $36.81M-0.8% | $37.1M+3.9% | $35.71M0.0% | $35.7M+3.7% | ||
| $26.24M-34.7% | $40.21M— | —— | —— | —— | ||
| $11.14M+76.1% | $6.33M+33.3% | $4.75M-1.7% | $4.83M-42.8% | $8.44M+2.1% | ||
| —— | —— | —— | —— | -$1.04M+67.1% | ||
| $19.25M+505% | $3.18M+472% | -$855K-772% | -$98K— | —— | ||
| —— | —— | —— | $146K-89.0% | $1.32M+19.5% | ||
| $343K-39.8% | $570K— | —— | —— | —— | ||
| -$169K— | $0+100% | -$690K-0.9% | -$684K-1.3% | -$675K-6.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$294.39M+3.5% | -$304.94M+4.6% | -$319.7M+8.5% | -$349.56M+5.6% | -$370.16M+5.4% | ||
| $4.5M+17.0% | $3.85M-23.9% | $5.05M-28.9% | $7.11M+5.3% | $6.75M-2.0% | ||
| $380.37M+57.6% | $241.37M+19.6% | $201.84M+850% | $21.25M-76.9% | $91.96M-34.4% | ||
| —— | —— | —— | —— | $107.92M-6.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $41K+46.4% | $28K+75.0% | $16K-38.5% | $26K-39.5% | $43K-32.8% | ||
| $8.06M+256% | $2.27M-8.6% | $2.48M-5.6% | $2.63M-6.2% | $2.8M-48.8% | ||
| $625.15M+56.2% | $400.24M-11.5% | $452.28M+53.7% | $294.34M+8.8% | $270.42M-4.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $75.84M+6.3% | $71.32M-3.1% | $73.6M-6.7% | $78.89M-6.1% | $84M-9.0% | ||
| $4.22M+53.7% | $2.75M+158% | $1.07M+59.7% | $667K-36.5% | $1.05M-29.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.04M+67.1% | ||
| —— | —— | —— | —— | $972K+27.4% | ||
| $19.25M+505% | $3.18M+472% | -$855K-772% | -$98K— | —— | ||
| $36.28M-12.0% | $41.23M-3.9% | $42.88M-2.7% | $44.08M+1.9% | $43.27M+13.8% | ||
| $250K0.0% | $250K+122% | -$1.15M+0.1% | -$1.15M0.0% | -$1.15M-0.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $14.02M+33.3% | $10.51M+50.0% | $7.01M+100% | $3.5M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $560.25K-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $107.92M-6.6% | ||
| $41K+46.4% | $28K+75.0% | $16K-38.5% | $26K-39.5% | $43K-32.8% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| $53.54M— | $0— | $0-100% | $15.62M-73.6% | $59.17M-19.3% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $245.88M+601% | -$49.09M-74.8% | -$28.08M+36.9% | -$44.5M-109% | -$21.31M-6.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $75M— | $0-100% | $24.24M-50.0% | $48.48M-33.3% | $72.72M-25.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $7.62M+29.2% | $5.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $429K+46.4% | $293K-71.6% | $1.03M+11.9% | $923K+14.7% | $805K0.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$298.89M+3.2% | -$308.78M+4.9% | -$324.76M+8.9% | -$356.66M+5.4% | -$376.91M+5.3% | ||
| -$298.89M+3.2% | -$308.78M+4.9% | -$324.76M+8.9% | -$356.66M+5.4% | -$376.91M+5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
